ClinicalTrials.gov
ClinicalTrials.gov Menu

Rhubarb and Angiotensin Converting Enzyme Inhibitor (RACE II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00672451
Recruitment Status : Terminated (unable to meet recruitment goal)
First Posted : May 6, 2008
Last Update Posted : November 6, 2017
Sponsor:
Collaborator:
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Wake Forest University Health Sciences ( Wake Forest University )

Brief Summary:
Rhubarb extract is a chinese herbal preparation that is used in china and other asian countries to treat constipation and chronic kidney disease. Use of angiotensin converting enzyme inhibitors (ACEI) in diabetic kidney disease has been shown to be beneficial in slowing progression. The purpose of this study is to determine the combined effect of rhubarb plus enalapril (an ACEI)in slowing the rate of decline of CKD in people with kidney disease from diabetes.

Condition or disease Intervention/treatment Phase
Diabetic Kidney Disease Dietary Supplement: rhubarb extract Dietary Supplement: placebo Not Applicable

Detailed Description:

Use of angiotensin converting enzyme inhibitors (ACEI) in diabetic nephropathy has been shown to be beneficial in slowing progression of disease. This would include use of ACEI, aggressive blood pressure and blood sugar control as well as other possible interventions. Experimental studies in chronic kidney disease (CKD) patients in China has suggested that rhubarb extract when used alone is equivalent to the protection afforded by ACEI. Furthermore when used in combination with ACEI, the renoprotective effect of rhubarb appears to be additive.

Rhubarb extract is a chinese herbal preparation that is used extensively in china and other asian countries to treat constipation and CKD. Its mechanism of action in preventing progression of CKD is uncertain but perhaps related to TGF beta and TNF alpha inhibition.

The specific aim is to determine the combined effect of rhubarb plus enalapril slowing the rate of decline of CKD (using Iothalamate GFRs) in patients in diabetes. A secondary aim would be to measure serum TGF beta concentrations over time and see if any observed decrease in the rate of decline of CKD is related to changes in TGF beta levels.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Rhubarb and Angiotensin Converting Enzyme Inhibitor
Study Start Date : January 2008
Actual Primary Completion Date : May 2009
Actual Study Completion Date : May 2009

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: rhubarb extract
will receive rhubarb extract
Dietary Supplement: rhubarb extract
titrate rhubarb extract titrated up to 6grams daily by mouth

Placebo Comparator: placebo
receive placebo
Dietary Supplement: placebo
placebo titrated up to 6 pills daily as patient tolerates




Primary Outcome Measures :
  1. albuminuria [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. rate of decline of GFR [ Time Frame: 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female patients >18 years
  2. Patients with diabetic nephropathy (history of type 1 or type 2 diabetes for > 7 years, no other cause for proteinuria listed in their medical chart). This is the definition used in most peer-reviewed trials44,45 of diabetic nephropathy. We do recognize that their proteinuria could be due to some other concomitant kidney disease but the only way to confirm that is to do a kidney biopsy which is not clinically justified.
  3. Proteinuria ≥ 0.5 g/day
  4. Ability to sign consent form

Exclusion Criteria:

  1. Pre study GFR (see section 10.7) < 20 ml/min
  2. Renal disease of etiologies other than diabetes
  3. Uncontrolled hypertension (Systolic BP >180 mmHg and Diastolic BP >110mm Hg)
  4. Patients with history of kidney stones in past 10 years
  5. Patients with active chronic liver disease (Liver enzymes ALT, AST >2.5 times normal)
  6. Patients with primary small bowel disease with malabsorption, blind loop syndrome, or jejunoileal bypass surgery (may cause unabsorbed fatty acids to combine with calcium which in turn causes too much absorption of oxalate)
  7. Patients with current alcohol, illicit drug use or any other condition (eg. Psychiatry disorder) that in the opinion of the investigator may interfere with the patient's ability to comply with the study
  8. Pregnant women or women of child bearing potential who are unwilling to use an adequate form of contraceptive during the course of the study (ACEI may be fetotoxic)
  9. Patients with significant unstable cardiovascular disease (NYHA class III and IV)
  10. Patients with active malignancy
  11. Uncontrolled infections.
  12. Patients with a known sensitivity to the study medications (including enalapril)
  13. Patients on angiotensin II receptor blockers (ARBs)
  14. Microscopic or macroscopic hematuria (to rule out kidney disease other than diabetic nephropathy)
  15. Patients on any herbal supplements unwilling to discontinue them
  16. Severe malnutrition (serum albumin <2.6mg/dL)
  17. Hyperkalemia at baseline, defined as serum potassium ≥ 5.5 mg/dL
  18. Iodine allergy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00672451


Locations
United States, North Carolina
Wake Forest University Heath Sciences
Winston-Salem, North Carolina, United States, 27157
Sponsors and Collaborators
Wake Forest University
National Institutes of Health (NIH)
Investigators
Principal Investigator: John Burkart, MD Wake Forest University Health Sciences

Responsible Party: Wake Forest University
ClinicalTrials.gov Identifier: NCT00672451     History of Changes
Other Study ID Numbers: 1R21AT002367-01A2 ( U.S. NIH Grant/Contract )
00000616-
Institutional IRB number
First Posted: May 6, 2008    Key Record Dates
Last Update Posted: November 6, 2017
Last Verified: November 2017

Keywords provided by Wake Forest University Health Sciences ( Wake Forest University ):
diabetic kidney disease
albuminuria

Additional relevant MeSH terms:
Kidney Diseases
Diabetic Nephropathies
Urologic Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Enzyme Inhibitors
Angiotensin-Converting Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protease Inhibitors